Onclive Team

Articles

Stephen J. Forman, MD, Transitioning from Chair of City of Hope

January 29th 2020

After more than 30 years of leadership as chair of City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, Stephen J. Forman, MD, has decided to transition out of this role.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

John Theurer Cancer Center Investigators Report Poor Colorectal Cancer Biomarker Testing Rates

January 14th 2020

Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey are the first to report poor adherence to genomic profiling guidelines for four biomarkers of metastatic colorectal cancer used to predict response to therapy, choose the most effective treatment, and improve outcomes — showing that only 40% of patients had their tumors tested.

Association of Community Cancer Centers Applauds Oncology Care Providers for Their Contribution to Record Drop in U.S. Cancer Deaths

January 13th 2020

The Association of Community Cancer Centers congratulates the entire oncology community on the achievement of the largest one-year drop in cancer mortality—the record decline in annual cancer deaths was measured from 2016 to 2017.

John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma

January 10th 2020

Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory multiple myeloma.

John Theurer Cancer Center Announces Appointment of Five New Physicians

January 10th 2020

Five new physicians have joined the medical staff at John Theurer Cancer Center at Hackensack University Cancer Center in New Jersey.

Brentuximab Vedotin Demonstrates Durable Long-Term PFS Benefit in Hodgkin Lymphoma

December 18th 2019

The addition of brentuximab vedotin to standard 3-drug chemotherapy for patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma continued to outperform a 4-drug chemotherapy standard.

ADC Targeting CD123 Active in R/R AML and BPDCN

December 18th 2019

IMGN632, an investigational anti-CD123 antibody-drug conjugate, demonstrated preliminary activity in patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm.

Resistance-Targeting BTK Inhibitor ARQ 531 Active Across B-Cell Malignancies

December 17th 2019

The investigational Bruton tyrosine kinase inhibitor ARQ 531 demonstrated safety and clinical activity across a range of B-cell malignancies.

Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk

December 16th 2019

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

December 14th 2019

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs

December 13th 2019

A subcutaneous fixed-dose combination of pertuzumab and trastuzumab demonstrated noninferiority to intravenous formulations of the 2 drugs with respect to pharmacokinetics, clinical activity, and safety, a randomized trial demonstrated.

Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer

December 13th 2019

Subcutaneous trastuzumab with hyaluronidase-oysk in combination with intravenous pertuzumab and chemotherapy had a safety profile consistent with IV trastuzumab in first-line metastatic HER2-positive breast cancer treatment.

Dual Anti-HER2 Therapy Reduces Recurrence Risk

December 13th 2019

A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate

December 12th 2019

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

Large PFS Gain With Daratumumab in Transplant-Ineligible Myeloma

December 11th 2019

More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.

Daratumumab Boosts Outcomes in Transplant-Eligible Myeloma

December 10th 2019

Adding an anti-CD38 antibody to a 3-drug chemotherapy-free regimen led to deeper and more frequent responses in patients with transplant-eligible, newly diagnosed multiple myeloma.

Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up

December 10th 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.

Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma

December 9th 2019

In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.

Triplet Regimen Induces High Rate of CR in R/R Follicular Lymphoma

December 8th 2019

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.